JP5082032B2 - 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物 - Google Patents

神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物 Download PDF

Info

Publication number
JP5082032B2
JP5082032B2 JP2004521935A JP2004521935A JP5082032B2 JP 5082032 B2 JP5082032 B2 JP 5082032B2 JP 2004521935 A JP2004521935 A JP 2004521935A JP 2004521935 A JP2004521935 A JP 2004521935A JP 5082032 B2 JP5082032 B2 JP 5082032B2
Authority
JP
Japan
Prior art keywords
dextromethorphan
quinidine
day
salt
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004521935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537268A (ja
JP2005537268A5 (US06780888-20040824-C00057.png
Inventor
ジェラルド ヤカタン、
ジェームス バーグ、
ローラ イー． ポウプ、
リチャード エー． スミス、
Original Assignee
アバニール ファーマシューティカルズ、 インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30116047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5082032(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アバニール ファーマシューティカルズ、 インク． filed Critical アバニール ファーマシューティカルズ、 インク．
Publication of JP2005537268A publication Critical patent/JP2005537268A/ja
Publication of JP2005537268A5 publication Critical patent/JP2005537268A5/ja
Application granted granted Critical
Publication of JP5082032B2 publication Critical patent/JP5082032B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2004521935A 2002-07-17 2003-07-17 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物 Expired - Lifetime JP5082032B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39666102P 2002-07-17 2002-07-17
US60/396,661 2002-07-17
PCT/US2003/022303 WO2004006930A1 (en) 2002-07-17 2003-07-17 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2011157054A Division JP2011225601A (ja) 2002-07-17 2011-07-15 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2012024387A Division JP2012116858A (ja) 2002-07-17 2012-02-07 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物

Publications (3)

Publication Number Publication Date
JP2005537268A JP2005537268A (ja) 2005-12-08
JP2005537268A5 JP2005537268A5 (US06780888-20040824-C00057.png) 2006-08-31
JP5082032B2 true JP5082032B2 (ja) 2012-11-28

Family

ID=30116047

Family Applications (12)

Application Number Title Priority Date Filing Date
JP2004521935A Expired - Lifetime JP5082032B2 (ja) 2002-07-17 2003-07-17 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2011157054A Pending JP2011225601A (ja) 2002-07-17 2011-07-15 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2012024387A Pending JP2012116858A (ja) 2002-07-17 2012-02-07 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2013272584A Pending JP2014058575A (ja) 2002-07-17 2013-12-27 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2014035209A Pending JP2014129384A (ja) 2002-07-17 2014-02-26 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2015182769A Expired - Lifetime JP6074000B2 (ja) 2002-07-17 2015-09-16 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2016051838A Expired - Lifetime JP6097859B2 (ja) 2002-07-17 2016-03-16 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2016225766A Expired - Lifetime JP6332651B2 (ja) 2002-07-17 2016-11-21 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2017027686A Pending JP2017088620A (ja) 2002-07-17 2017-02-17 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2018106910A Pending JP2018150368A (ja) 2002-07-17 2018-06-04 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2019191618A Pending JP2020063248A (ja) 2002-07-17 2019-10-21 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2021039908A Withdrawn JP2021098743A (ja) 2002-07-17 2021-03-12 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物

Family Applications After (11)

Application Number Title Priority Date Filing Date
JP2011157054A Pending JP2011225601A (ja) 2002-07-17 2011-07-15 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2012024387A Pending JP2012116858A (ja) 2002-07-17 2012-02-07 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2013272584A Pending JP2014058575A (ja) 2002-07-17 2013-12-27 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2014035209A Pending JP2014129384A (ja) 2002-07-17 2014-02-26 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2015182769A Expired - Lifetime JP6074000B2 (ja) 2002-07-17 2015-09-16 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2016051838A Expired - Lifetime JP6097859B2 (ja) 2002-07-17 2016-03-16 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2016225766A Expired - Lifetime JP6332651B2 (ja) 2002-07-17 2016-11-21 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2017027686A Pending JP2017088620A (ja) 2002-07-17 2017-02-17 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2018106910A Pending JP2018150368A (ja) 2002-07-17 2018-06-04 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2019191618A Pending JP2020063248A (ja) 2002-07-17 2019-10-21 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP2021039908A Withdrawn JP2021098743A (ja) 2002-07-17 2021-03-12 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物

Country Status (24)

Country Link
US (12) US7659282B2 (US06780888-20040824-C00057.png)
EP (6) EP1980252B1 (US06780888-20040824-C00057.png)
JP (12) JP5082032B2 (US06780888-20040824-C00057.png)
KR (7) KR20120089706A (US06780888-20040824-C00057.png)
AT (1) ATE399553T1 (US06780888-20040824-C00057.png)
AU (3) AU2003251971B9 (US06780888-20040824-C00057.png)
BE (1) BE2013C064I2 (US06780888-20040824-C00057.png)
CA (1) CA2492081C (US06780888-20040824-C00057.png)
CY (2) CY1110405T1 (US06780888-20040824-C00057.png)
DE (1) DE60321929D1 (US06780888-20040824-C00057.png)
DK (2) DK1980252T3 (US06780888-20040824-C00057.png)
ES (2) ES2553654T3 (US06780888-20040824-C00057.png)
FR (1) FR13C0062I2 (US06780888-20040824-C00057.png)
HK (2) HK1076052A1 (US06780888-20040824-C00057.png)
HU (2) HUE028100T2 (US06780888-20040824-C00057.png)
IL (7) IL166166A0 (US06780888-20040824-C00057.png)
LU (1) LU92323I2 (US06780888-20040824-C00057.png)
NO (2) NO330626B1 (US06780888-20040824-C00057.png)
PL (2) PL213552B1 (US06780888-20040824-C00057.png)
PT (2) PT1539166E (US06780888-20040824-C00057.png)
RU (1) RU2341265C2 (US06780888-20040824-C00057.png)
SI (2) SI1539166T1 (US06780888-20040824-C00057.png)
TW (1) TWI326214B (US06780888-20040824-C00057.png)
WO (1) WO2004006930A1 (US06780888-20040824-C00057.png)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7754767B2 (en) * 2002-11-06 2010-07-13 Trinity Laboratories, Inc. Method for treatment of premature ejaculation in humans
JP2007530664A (ja) * 2004-03-30 2007-11-01 ペインセプター ファーマ コーポレーション ゲートイオンチャンネルを調節するための組成物及び方法
US20070191411A1 (en) * 2004-10-07 2007-08-16 Smith Richard A Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
JP2009525343A (ja) * 2006-02-03 2009-07-09 アバニール・ファーマシューティカルズ 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
US20160143901A1 (en) * 2006-02-03 2016-05-26 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
MX341177B (es) 2007-05-01 2016-08-10 Concert Pharmaceuticals Inc Compuestos de morfina.
PL2522667T3 (pl) 2007-05-01 2015-01-30 Concert Pharmaceuticals Inc Związki morfinanu
CA3208128A1 (en) 2007-05-01 2008-11-13 Sun Pharmaceutical Industries, Inc. Morphinan compounds
WO2009006194A1 (en) * 2007-06-28 2009-01-08 Avanir Pharmaceuticals Pharmaceutical compositions for the treatment of involuntary emotional expression disorder
ES2750825T3 (es) 2008-09-19 2020-03-27 Concert Pharmaceuticals Inc Compuestos de morfinano deuterados
US20120122848A1 (en) * 2009-07-29 2012-05-17 Green Cross Corporation (+)-3-hydroxymorphinan derivatives as neuroprotectants
CA2712848A1 (en) * 2009-08-28 2011-02-28 Avanir Pharmaceuticals, Inc. A method of reducing cns and gastrointestinal side affects associated with long-term, dextromethorphan/low-dose quinidine combination therapy
KR20130061148A (ko) * 2010-05-03 2013-06-10 티에스에이치 바이오팜 코포레이션 리미티드 고혈압 치료용 약학 조성물 및 방법
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
US8569328B1 (en) * 2011-05-24 2013-10-29 Antecip Bioventures Ii Llc Compositions and methods comprising tilidine or related compounds and dextromethorphan
JP6094578B2 (ja) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝性障害の治療のためのｇｐｒ１１９モジュレーターとしての置換ピペリジン
US20130274282A1 (en) * 2012-04-16 2013-10-17 Herriot Tabuteau Compositions and methods comprising celecoxib or related compounds and dextromethorphan
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
CN103073496B (zh) * 2013-02-18 2015-08-26 苏州立新制药有限公司 右美沙芬的制备方法
US10716784B2 (en) * 2013-03-07 2020-07-21 Mindlab LLC Pain medicine combination and uses thereof
US11426370B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298351B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11058648B2 (en) 2013-11-05 2021-07-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617747B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11617728B2 (en) 2013-11-05 2023-04-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11596627B2 (en) 2013-11-05 2023-03-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20220233470A1 (en) 2013-11-05 2022-07-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10898453B2 (en) 2013-11-05 2021-01-26 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11096937B2 (en) 2013-11-05 2021-08-24 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11090300B2 (en) 2013-11-05 2021-08-17 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10780064B2 (en) 2019-01-07 2020-09-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10874665B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11541048B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966942B2 (en) 2019-01-07 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10786469B2 (en) 2013-11-05 2020-09-29 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10894047B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11229640B2 (en) 2013-11-05 2022-01-25 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US10933034B2 (en) 2013-11-05 2021-03-02 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273133B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11234946B2 (en) 2013-11-05 2022-02-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11419867B2 (en) 2013-11-05 2022-08-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11969421B2 (en) 2013-11-05 2024-04-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457023B1 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10940124B2 (en) 2019-01-07 2021-03-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11191739B2 (en) 2013-11-05 2021-12-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11517543B2 (en) 2013-11-05 2022-12-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11478468B2 (en) 2013-11-05 2022-10-25 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9700528B2 (en) 2013-11-05 2017-07-11 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11197839B2 (en) 2013-11-05 2021-12-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10105327B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
US11497721B2 (en) 2013-11-05 2022-11-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9861595B2 (en) 2013-11-05 2018-01-09 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10105361B2 (en) 2013-11-05 2018-10-23 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10874664B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9402843B2 (en) 2013-11-05 2016-08-02 Antecip Bioventures Ii Llc Compositions and methods of using threohydroxybupropion for therapeutic purposes
US11541021B2 (en) 2013-11-05 2023-01-03 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US20200338022A1 (en) 2019-01-07 2020-10-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11273134B2 (en) 2013-11-05 2022-03-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11524007B2 (en) 2013-11-05 2022-12-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10881657B2 (en) 2013-11-05 2021-01-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10512643B2 (en) 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10874663B2 (en) 2013-11-05 2020-12-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9457025B2 (en) 2013-11-05 2016-10-04 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US11364233B2 (en) 2013-11-05 2022-06-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11020389B2 (en) 2013-11-05 2021-06-01 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11298352B2 (en) 2013-11-05 2022-04-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285118B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11207281B2 (en) 2013-11-05 2021-12-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10813924B2 (en) 2018-03-20 2020-10-27 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
US11065248B2 (en) 2013-11-05 2021-07-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11129826B2 (en) 2013-11-05 2021-09-28 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US20160324807A1 (en) 2013-11-05 2016-11-10 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11426401B2 (en) 2013-11-05 2022-08-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11253491B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10772850B2 (en) 2013-11-05 2020-09-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11185515B2 (en) 2013-11-05 2021-11-30 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11534414B2 (en) 2013-11-05 2022-12-27 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966974B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11141416B2 (en) 2013-11-05 2021-10-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11382874B2 (en) 2013-11-05 2022-07-12 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123344B2 (en) 2013-11-05 2021-09-21 Axsome Therapeutics, Inc. Bupropion as a modulator of drug activity
US20160361305A1 (en) 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
US9198905B2 (en) 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US11007189B2 (en) 2013-11-05 2021-05-18 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11590124B2 (en) 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11357744B2 (en) 2013-11-05 2022-06-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10799497B2 (en) 2013-11-05 2020-10-13 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
US11291665B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9968568B2 (en) 2013-11-05 2018-05-15 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US10945973B2 (en) 2013-11-05 2021-03-16 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11285146B2 (en) 2013-11-05 2022-03-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10080727B2 (en) 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11510918B2 (en) 2013-11-05 2022-11-29 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9867819B2 (en) 2013-11-05 2018-01-16 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11213521B2 (en) 2013-11-05 2022-01-04 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11147808B2 (en) 2013-11-05 2021-10-19 Antecip Bioventures Ii Llc Method of decreasing the fluctuation index of dextromethorphan
US11576909B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10966941B2 (en) 2013-11-05 2021-04-06 Antecip Bioventures Ii Llp Bupropion as a modulator of drug activity
US11344544B2 (en) 2013-11-05 2022-05-31 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11123343B2 (en) 2013-11-05 2021-09-21 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10980800B2 (en) 2013-11-05 2021-04-20 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11571399B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10864209B2 (en) 2013-11-05 2020-12-15 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10894046B2 (en) 2013-11-05 2021-01-19 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9408815B2 (en) 2013-11-05 2016-08-09 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US10688066B2 (en) 2018-03-20 2020-06-23 Antecip Bioventures Ii Llc Bupropion and dextromethorphan for treating nicotine addiction
NZ758432A (en) * 2013-11-05 2021-07-30 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US9707191B2 (en) 2013-11-05 2017-07-18 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11571417B2 (en) 2013-11-05 2023-02-07 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11291638B2 (en) 2013-11-05 2022-04-05 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11439636B1 (en) 2013-11-05 2022-09-13 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US9474731B1 (en) 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US11253492B2 (en) 2013-11-05 2022-02-22 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
US11576877B2 (en) 2013-11-05 2023-02-14 Antecip Bioventures Ii Llc Bupropion as modulator of drug activity
US11311534B2 (en) 2013-11-05 2022-04-26 Antecip Bio Ventures Ii Llc Bupropion as a modulator of drug activity
US9763932B2 (en) 2013-11-05 2017-09-19 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
RU2020116666A (ru) * 2014-09-14 2020-07-31 Аванир Фармасьютикалз, Инк. Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
US20160184290A1 (en) * 2014-12-31 2016-06-30 Paul J. Markovitz Method of treating schizophrenia
CA2994157A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for treating agitation
WO2017117347A1 (en) * 2015-12-30 2017-07-06 Markovitz M D Paul Method of treating schizophrenia
JP7061079B2 (ja) 2016-07-04 2022-04-27 アヴェニール ファーマシューティカルズ， インコーポレイテッド 重水素化デキストロメトルファンの合成方法
WO2018031216A1 (en) * 2016-08-12 2018-02-15 Steven Rothman Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
JP7096813B2 (ja) * 2016-08-26 2022-07-06 エクシーバ ゲーエムベーハー 組成物及びその方法
CA3138116A1 (en) * 2017-05-04 2018-11-08 Exciva GmbH Novel compositions, combinations, and methods thereof
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
TWI795446B (zh) 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
US10925842B2 (en) 2019-01-07 2021-02-23 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
CN114469882B (zh) * 2022-04-06 2023-10-20 北京剂泰医药科技有限公司 一种右美沙芬奎尼丁口崩片及其应用
CN114569742B (zh) * 2022-05-09 2022-07-19 北京剂泰医药科技有限公司 一种组合物及其制备方法和应用
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4316888A (en) 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
US5034400A (en) 1989-10-20 1991-07-23 Olney John W Method for preventing neurotoxic side effects of NMDA antagonists
JP2893866B2 (ja) * 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
US5863927A (en) 1994-09-22 1999-01-26 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
ES2163648T3 (es) * 1995-08-03 2002-02-01 Dade Behring Inc Conjugados de quinidina y su uso en inmunoensayos.
CA2343321A1 (en) 1998-09-21 2000-03-30 Transgene S.A. Pharmaceutical composition for the pre-treatment of a patient in need of drug or pro-drug
SK13832001A3 (sk) * 1999-04-07 2004-01-08 Pfizer Products Inc. Použitie inhibítorov CYP2D6 v kombinovanej liečbe
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US20040087479A1 (en) 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
JP2009525343A (ja) * 2006-02-03 2009-07-09 アバニール・ファーマシューティカルズ 鬱病、不安および神経変性疾患を治療するためのデキストロメトルファンおよびキニジンを含む薬剤組成物
KR101590378B1 (ko) * 2009-09-07 2016-02-02 에스케이텔레콤 주식회사 근거리 영역 내의 방송통신 융합 구간에 대한 신호 간섭 최소화 시스템 및 방법, 그리고 이에 적용되는 장치

Also Published As

Publication number Publication date
DK1980252T3 (en) 2015-11-30
HK1076052A1 (en) 2006-01-06
RU2005104418A (ru) 2005-10-27
US20200276185A1 (en) 2020-09-03
JP2005537268A (ja) 2005-12-08
JP2018150368A (ja) 2018-09-27
US20050203125A1 (en) 2005-09-15
JP2020063248A (ja) 2020-04-23
AU2010212348A1 (en) 2010-09-09
IL225192A (en) 2017-12-31
NO330626B1 (no) 2011-05-30
IL225191A (en) 2017-03-30
PT1539166E (pt) 2008-10-14
EP1980252B1 (en) 2015-08-19
US20180098984A1 (en) 2018-04-12
IL166166A0 (en) 2006-01-15
IL225190A (en) 2017-03-30
LU92323I2 (fr) 2015-09-22
FR13C0062I1 (US06780888-20040824-C00057.png) 2014-01-03
NO2013017I1 (no) 2014-06-02
US20130072517A1 (en) 2013-03-21
EP3281630A1 (en) 2018-02-14
JP2011225601A (ja) 2011-11-10
EP3459547A1 (en) 2019-03-27
IL267381A (en) 2019-08-29
KR20050043893A (ko) 2005-05-11
US20090082384A1 (en) 2009-03-26
IL225191A0 (en) 2013-06-27
US20160287576A1 (en) 2016-10-06
AU2003251971A1 (en) 2004-02-02
SI1980252T1 (sl) 2016-01-29
KR101622446B1 (ko) 2016-05-18
CY2013041I2 (el) 2015-12-09
AU2010212348B2 (en) 2013-05-09
ES2309351T3 (es) 2008-12-16
AU2008201775B2 (en) 2010-05-20
US20140288114A1 (en) 2014-09-25
PL374026A1 (en) 2005-09-19
CA2492081C (en) 2010-09-07
US20120165363A1 (en) 2012-06-28
AU2008201775A1 (en) 2008-05-15
US8227484B2 (en) 2012-07-24
ATE399553T1 (de) 2008-07-15
US20150209347A1 (en) 2015-07-30
EP1980252A3 (en) 2008-12-24
KR20190143466A (ko) 2019-12-30
KR20130043217A (ko) 2013-04-29
NO20050807L (no) 2005-02-15
KR20120089706A (ko) 2012-08-13
EP1539166A1 (en) 2005-06-15
PL398445A1 (pl) 2012-06-04
JP2014129384A (ja) 2014-07-10
ES2553654T3 (es) 2015-12-10
JP2017088620A (ja) 2017-05-25
US20140045880A1 (en) 2014-02-13
AU2003251971B2 (en) 2008-02-21
AU2003251971B9 (en) 2008-04-24
HUS1300069I1 (hu) 2016-10-28
JP2016106150A (ja) 2016-06-16
RU2341265C2 (ru) 2008-12-20
CA2492081A1 (en) 2004-01-22
BE2013C064I2 (US06780888-20040824-C00057.png) 2022-08-09
EP1539166B1 (en) 2008-07-02
EP2322179A1 (en) 2011-05-18
DE60321929D1 (de) 2008-08-14
KR101588095B1 (ko) 2016-01-25
TW200403997A (en) 2004-03-16
EP1980252A2 (en) 2008-10-15
KR20110010669A (ko) 2011-02-01
KR20160055963A (ko) 2016-05-18
KR20130041296A (ko) 2013-04-24
CY2013041I1 (el) 2015-12-09
JP6097859B2 (ja) 2017-03-15
WO2004006930A1 (en) 2004-01-22
JP2017036337A (ja) 2017-02-16
FR13C0062I2 (fr) 2015-11-20
PL213552B1 (pl) 2013-03-29
JP6332651B2 (ja) 2018-05-30
TWI326214B (en) 2010-06-21
DK1539166T3 (da) 2008-10-20
CY1110405T1 (el) 2012-05-23
US7659282B2 (en) 2010-02-09
US20190201391A1 (en) 2019-07-04
JP2021098743A (ja) 2021-07-01
IL256054A (en) 2018-01-31
JP2012116858A (ja) 2012-06-21
JP2016011304A (ja) 2016-01-21
NO2013017I2 (no) 2015-09-07
JP6074000B2 (ja) 2017-02-01
PT1980252E (pt) 2015-12-01
JP2014058575A (ja) 2014-04-03
EP3824889A1 (en) 2021-05-26
US20100137352A1 (en) 2010-06-03
IL211593A0 (en) 2011-05-31
HUE028100T2 (en) 2016-11-28
HK1123741A1 (en) 2009-06-26
SI1539166T1 (sl) 2008-12-31

Similar Documents

Publication Publication Date Title
JP6332651B2 (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
AU2017202884B2 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100519

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120321

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20120420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120723

R150 Certificate of patent or registration of utility model

Ref document number: 5082032

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150914

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term